Loading…

HDL-like discs for assaying membrane proteins in drug discovery

To broaden the use of the recombinant high-density lipoprotein (rHDL) approach to the characterization of lead compounds, we investigated the pharmacology of the human beta-2-adrenoceptor in nanolipid bilayers (rHDL) with a broad set of beta-adrenoceptor antagonists. To that end, we developed a homo...

Full description

Saved in:
Bibliographic Details
Published in:Biophysical chemistry 2012-05, Vol.165-166, p.56-61
Main Authors: Fiez-Vandal, Cédric, Leder, Lukas, Freuler, Felix, Sykes, David, Charlton, Steven J., Siehler, Sandra, Schopfer, Ulrich, Duckely, Myriam
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To broaden the use of the recombinant high-density lipoprotein (rHDL) approach to the characterization of lead compounds, we investigated the pharmacology of the human beta-2-adrenoceptor in nanolipid bilayers (rHDL) with a broad set of beta-adrenoceptor antagonists. To that end, we developed a homogeneous copper-chelate scintillation proximity binding assay (SPA) in order to compare receptor-ligand binding affinities before and after reconstitution into rHDLs. Our results clearly show that the beta-2-adrenoceptor reconstituted in rHDLs display the same pharmacology as that in cell membranes and that rHDLs can be used not only to measure affinities for a range of ligands but also to study binding kinetics. [Display omitted] ► A SPA-based homogeneous assay allowing the study of ligand binding to the β2AR. ► β2AR has the same pharmacology in rHDLs than in cell membranes for a set of antagonists. ► Antagonist binding is right-shifted to lower affinities for the solubilized receptor. ► rHDL-like discs can be used for compound screening and lead optimization.
ISSN:0301-4622
1873-4200
DOI:10.1016/j.bpc.2012.03.005